Assignee
BIOVERATIV USA INC
US·10 granted patents·15 pending applications·34 citations·filing 2016–2025
Top patents by PatentIndex Score
25 records- 0197US11246926B2Polynucleotides encoding anti-C1s antibodiesBIOVERATIV USA INC·Filed 2020·Granted Feb 15, 2022·4 cites·11 claims
- 0294US10729767B2Humanized anti-C1s antibodies and methods of inhibiting C1s cleavageBIOVERATIV USA INC·Filed 2016·Granted Aug 4, 2020·9 cites·32 claims
- 0393US12215169B2Anti-complement C1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Feb 4, 2025·1 cites·21 claims
- 0493US10450382B2Anti-complement C1s antibodiesBIOVERATIV USA INC·Filed 2016·Granted Oct 22, 2019·8 cites·9 claims
- 0592US2025263503A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 0690US10457745B2Anti-complement C1s antibodiesBIOVERATIV USA INC·Filed 2016·Granted Oct 29, 2019·6 cites·10 claims
- 0786US10934347B2Anti-complement factor BB antibodies and uses thereofBIOVERATIV USA INC·Filed 2017·Granted Mar 2, 2021·4 cites·15 claims
- 0883US12391750B2Anti-C1S antibodies and methods of use thereofBIOVERATIV USA INC·Filed 2023·Granted Aug 19, 2025·0 cites·16 claims
- 0982US12240917B2Anti-complement C1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Mar 4, 2025·0 cites·13 claims
- 1082US2025188192A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2025·Application pending·0 cites
- 1182US2026092104A1Anti-c1s antibodies and methods of use thereofBIOVERATIV USA INC·Filed 2025·Application pending·0 cites
- 1279US11192944B2Methods of inducing complement activityBIOVERATIV USA INC·Filed 2018·Granted Dec 7, 2021·2 cites·13 claims
- 1378US2025295768A1Methods of treating autoimmune and alloimmune disordersBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 1474US2023218753A1Humanized anti-c1s antibodies and methods of use thereofBIOVERATIV USA INC·Filed 2022·Application pending·0 cites
- 1572US2020079875A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2019·Application pending·0 cites
- 1670US2025145696A1Methods for treating complement-mediated diseases and disordersBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 1769US11851482B2Anti-complement factor Bb antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Dec 26, 2023·0 cites·20 claims
- 1868US2020079876A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2019·Application pending·0 cites
- 1966US2022249664A1Methods of treating autoimmune and alloimmune disordersBIOVERATIV USA INC·Filed 2021·Application pending·0 cites
- 2060US2024052062A1Reducing surgery-associated hemolysis in cold agglutinin disease patientsBIOVERATIV USA INC·Filed 2023·Application pending·0 cites
- 2158US2023357433A1Inflammatory cytokines and fatigue in subject with a complement mediated diseaseBIOVERATIV USA INC·Filed 2023·Application pending·0 cites
- 2258US2024025978A1Methods for treating complement-mediated diseasesBIOVERATIV USA INC·Filed 2023·Application pending·0 cites
- 2354US2020048332A1Anti-c1s antibodies and methods of use thereofBIOVERATIV USA INC·Filed 2017·Application pending·0 cites
- 2450US2024117021A1Anti-complement c1s antibody formulationBIOVERATIV USA INC·Filed 2023·Application pending·0 cites
- 2548US2021115116A1Methods for treating complement-mediated diseases and disordersBIOVERATIV USA INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BIOVERATIV USA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →